---
document_datetime: 2025-11-23 08:35:03
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/bondronat.html
document_name: bondronat.html
version: success
processing_time: 0.1252806
conversion_datetime: 2025-12-24 07:10:47.377675
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Bondronat

[RSS](/en/individual-human-medicine.xml/65529)

##### Authorised

This medicine is authorised for use in the European Union

ibandronic acid

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Bondronat](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Bondronat. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Bondronat.

Expand section

Collapse section

## What is Bondronat?

Bondronat is a medicine that contains the active substance ibandronic acid. It is available as a concentrate that is made up into a solution for infusion (drip) into a vein, and as tablets (50 mg).

## What is Bondronat used for?

Bondronat is used in adults in the following ways:

- as an infusion or as a tablet to prevent 'skeletal events' (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone);
- as an infusion to treat hypercalcaemia (high levels of calcium in the blood) caused by tumours.

The medicine can only be obtained with a prescription.

## How is Bondronat used?

Bondronat treatment should only be started by a doctor who has experience in the treatment of cancer.

In the prevention of skeletal events, Bondronat is either given as a 6?mg infusion lasting at least 15 minutes every three to four weeks, or as one tablet once a day. The tablet should be taken after the patient has not eaten anything for at least six hours overnight and at least 30 minutes before the first food or drink of the day. It should be taken with a full glass of plain water (in areas with hard water, where tap water contains a lot of dissolved calcium, bottled water with a low mineral content may be used). The patient should not lie down for one hour after taking the tablet. Patients with moderate or severe kidney problems should receive Bondronat infusions at a lower dose over an hour, or the tablet every two days or every week.

In the treatment of hypercalcaemia caused by tumours, Bondronat is given over 2 hours as an infusion of either 2 or 4 mg, depending on how severe the hypercalcaemia is. The infusion will normally bring the blood calcium level down to normal levels within a week.

## How does Bondronat work?

The active substance in Bondronat, ibandronic acid, is a bisphosphonate. It stops the action of the osteoclasts, the cells in the body that are involved in breaking down the bone tissue. This leads to less bone loss. The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.

Patients with tumours can have high levels of calcium in their blood, released from the bones. By preventing the breakdown of bones, Bondronat also helps to reduce the amount of calcium released into the blood.

## How has Bondronat been studied?

In the prevention of skeletal events in patients with breast cancer and bone metastases, Bondronat has been compared with placebo (a dummy treatment) in three main studies lasting two years: one with the infusions in 466 patients and two with the tablets in a total of 846 patients. The main measure of effectiveness was based on the number of new bone complications. These included spine fractures, fractures outside the spine and any bone complications that needed treatment with radiotherapy or surgery.

Bondronat has also been studied in the treatment of hypercalcaemia caused by tumours in three four-week studies involving a total of 343 patients. Bondronat was not compared with any other treatments in these studies. The main measure of effectiveness was the change in blood calcium levels.

## What benefit has Bondronat shown during the studies?

Bondronat was more effective than placebo in preventing bone complications. It took longer for patients on Bondronat infusions or tablets to develop a new bone complication (50 to 76 weeks) than for patients on placebo (33 to 48 weeks). Bondronat reduced the risk of having a skeletal event by about 40% compared with placebo.

Bondronat was also effective in treating hypercalcaemia caused by tumours. About a half to two-thirds of the patients responded to a 2-mg dose of Bondronat, with blood calcium levels returning to within the normal range. About three-quarters responded to a 4-mg dose.

## What is the risk associated with Bondronat?

The most common side effects with Bondronat infusions are a rise in body temperature, hypocalcaemia (low blood calcium levels), asthenia (weakness) and headache. The most common side effects with the tablets are hypocalcaemia and dyspepsia (heartburn). The most serious side effects with Bondronat are anaphylactic reaction (severe allergic reaction), atypical fractures of the femur (an unusual type of fracture of the bone of the upper leg), osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth), and eye inflammation.

Bondronat must not be used in people with hypocalcaemia. The tablets must not be used in patients who have abnormalities of the oesophagus or who cannot stand or sit up for at least an hour. For the full list of all side effects and restrictions reported with Bondronat, see the package leaflet.

## Why has Bondronat been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Bondronat's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Bondronat?

A risk management plan has been developed to ensure that Bondronat is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Bondronat, including the appropriate precautions to be followed by healthcare professionals and patients.

In addition, the company that markets Bondronat will provide a card to inform patients receiving Bondronat infusion about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms.

## Other information about Bondronat

The European Commission granted a marketing authorisation valid throughout the European Union for Bondronat on 25 June 1996.

For more information about treatment with Bondronat, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Bondronat : EPAR - Summary for the public

English (EN) (82.89 KB - PDF)

**First published:** 09/06/2008

**Last updated:** 13/05/2016

[View](/en/documents/overview/bondronat-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-81)

български (BG) (110.74 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/bg/documents/overview/bondronat-epar-summary-public_bg.pdf)

español (ES) (82.93 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/es/documents/overview/bondronat-epar-summary-public_es.pdf)

čeština (CS) (110.35 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/cs/documents/overview/bondronat-epar-summary-public_cs.pdf)

dansk (DA) (82.29 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/da/documents/overview/bondronat-epar-summary-public_da.pdf)

Deutsch (DE) (84.1 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/de/documents/overview/bondronat-epar-summary-public_de.pdf)

eesti keel (ET) (81.2 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/et/documents/overview/bondronat-epar-summary-public_et.pdf)

ελληνικά (EL) (112.27 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/el/documents/overview/bondronat-epar-summary-public_el.pdf)

français (FR) (83.94 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/fr/documents/overview/bondronat-epar-summary-public_fr.pdf)

hrvatski (HR) (102.87 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/hr/documents/overview/bondronat-epar-summary-public_hr.pdf)

italiano (IT) (82.1 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/it/documents/overview/bondronat-epar-summary-public_it.pdf)

latviešu valoda (LV) (112.6 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/lv/documents/overview/bondronat-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (107.84 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/lt/documents/overview/bondronat-epar-summary-public_lt.pdf)

magyar (HU) (103.49 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/hu/documents/overview/bondronat-epar-summary-public_hu.pdf)

Malti (MT) (117.71 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/mt/documents/overview/bondronat-epar-summary-public_mt.pdf)

Nederlands (NL) (82.9 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/nl/documents/overview/bondronat-epar-summary-public_nl.pdf)

polski (PL) (109.81 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/pl/documents/overview/bondronat-epar-summary-public_pl.pdf)

português (PT) (83.06 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/pt/documents/overview/bondronat-epar-summary-public_pt.pdf)

română (RO) (105.91 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/ro/documents/overview/bondronat-epar-summary-public_ro.pdf)

slovenčina (SK) (109.07 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/sk/documents/overview/bondronat-epar-summary-public_sk.pdf)

slovenščina (SL) (102.09 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/sl/documents/overview/bondronat-epar-summary-public_sl.pdf)

Suomi (FI) (81.62 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/fi/documents/overview/bondronat-epar-summary-public_fi.pdf)

svenska (SV) (82.29 KB - PDF)

**First published:**

09/06/2008

**Last updated:**

13/05/2016

[View](/sv/documents/overview/bondronat-epar-summary-public_sv.pdf)

Bondronat : EPAR - Risk management plan

English (EN) (697.95 KB - PDF)

**First published:** 16/09/2024

[View](/en/documents/rmp/bondronat-epar-risk-management-plan_en.pdf)

## Product information

Bondronat : EPAR - Product Information

English (EN) (687.59 KB - PDF)

**First published:** 09/10/2007

**Last updated:** 08/04/2024

[View](/en/documents/product-information/bondronat-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-771)

български (BG) (800.77 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/bg/documents/product-information/bondronat-epar-product-information_bg.pdf)

español (ES) (660.83 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/es/documents/product-information/bondronat-epar-product-information_es.pdf)

čeština (CS) (735.04 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/cs/documents/product-information/bondronat-epar-product-information_cs.pdf)

dansk (DA) (720.46 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/da/documents/product-information/bondronat-epar-product-information_da.pdf)

Deutsch (DE) (656.25 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/de/documents/product-information/bondronat-epar-product-information_de.pdf)

eesti keel (ET) (682.3 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/et/documents/product-information/bondronat-epar-product-information_et.pdf)

ελληνικά (EL) (854.9 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/el/documents/product-information/bondronat-epar-product-information_el.pdf)

français (FR) (736.28 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/fr/documents/product-information/bondronat-epar-product-information_fr.pdf)

hrvatski (HR) (749.23 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/hr/documents/product-information/bondronat-epar-product-information_hr.pdf)

íslenska (IS) (624.3 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/is/documents/product-information/bondronat-epar-product-information_is.pdf)

italiano (IT) (742.33 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/it/documents/product-information/bondronat-epar-product-information_it.pdf)

latviešu valoda (LV) (791.16 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/lv/documents/product-information/bondronat-epar-product-information_lv.pdf)

lietuvių kalba (LT) (753.16 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/lt/documents/product-information/bondronat-epar-product-information_lt.pdf)

magyar (HU) (744.4 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/hu/documents/product-information/bondronat-epar-product-information_hu.pdf)

Malti (MT) (885.07 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/mt/documents/product-information/bondronat-epar-product-information_mt.pdf)

Nederlands (NL) (650.24 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/nl/documents/product-information/bondronat-epar-product-information_nl.pdf)

norsk (NO) (767.17 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/no/documents/product-information/bondronat-epar-product-information_no.pdf)

polski (PL) (864.22 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/pl/documents/product-information/bondronat-epar-product-information_pl.pdf)

português (PT) (614.47 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/pt/documents/product-information/bondronat-epar-product-information_pt.pdf)

română (RO) (972.06 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/ro/documents/product-information/bondronat-epar-product-information_ro.pdf)

slovenčina (SK) (923.61 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/sk/documents/product-information/bondronat-epar-product-information_sk.pdf)

slovenščina (SL) (740.8 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/sl/documents/product-information/bondronat-epar-product-information_sl.pdf)

Suomi (FI) (710.22 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/fi/documents/product-information/bondronat-epar-product-information_fi.pdf)

svenska (SV) (692.27 KB - PDF)

**First published:**

09/10/2007

**Last updated:**

08/04/2024

[View](/sv/documents/product-information/bondronat-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** H/C/WS2451 25/01/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Bondronat : EPAR - All Authorised presentations

English (EN) (15.54 KB - PDF)

**First published:** 12/06/2008

**Last updated:** 12/06/2008

[View](/en/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_en.pdf)

[Other languages (18)](#file-language-dropdown-976)

español (ES) (15.71 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/es/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_es.pdf)

čeština (CS) (101.55 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/cs/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.62 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/da/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.71 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/de/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.72 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/et/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (98.98 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/el/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_el.pdf)

français (FR) (15.71 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/fr/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (15.19 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/it/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (101.54 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/lv/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (103.48 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/lt/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (101.54 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/hu/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (15.16 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/nl/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_nl.pdf)

polski (PL) (104.3 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/pl/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.74 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/pt/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (101.64 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/sk/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (15.39 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/sl/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.52 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/fi/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.64 KB - PDF)

**First published:**

12/06/2008

**Last updated:**

12/06/2008

[View](/sv/documents/all-authorised-presentations/bondronat-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Bondronat Active substance ibandronic acid International non-proprietary name (INN) or common name ibandronic acid Therapeutic area (MeSH)

- Hypercalcemia
- Breast Neoplasms
- Neoplasm Metastasis
- Fractures, Bone

Anatomical therapeutic chemical (ATC) code M05BA06

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Bondronat is indicated for:

- prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;
- treatment of tumour-induced hypercalcaemia with or without metastases.

## Authorisation details

EMA product number EMEA/H/C/000101 Marketing authorisation holder

Atnahs Pharma Netherlands B.V.

Copenhagen Towers,

Opinion adopted 14/02/1996 Marketing authorisation issued 25/06/1996 Revision 34

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Bondronat : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (300.87 KB - PDF)

**First published:** 09/10/2007

**Last updated:** 08/04/2024

[View](/en/documents/procedural-steps-after/bondronat-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Bondronat-H-C-PSUSA/00001702/201506 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/231942/2016

English (EN) (70.94 KB - PDF)

**First published:** 13/05/2016

**Last updated:** 13/05/2016

[View](/en/documents/scientific-conclusion/bondronat-h-c-psusa00001702201506-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Bondronat-H-C-101-A20-51 : EPAR : Assessment Report - Article 20

Adopted

Reference Number: EMA/543434/2011

English (EN) (127.28 KB - PDF)

**First published:** 13/09/2011

**Last updated:** 13/09/2011

[View](/en/documents/variation-report/bondronat-h-c-101-a20-51-epar-assessment-report-article-20_en.pdf)

CHMP post-authorisation summary of positive opinion for Bondronat

Adopted

Reference Number: EMA/824754/2009

English (EN) (37.33 KB - PDF)

**First published:** 17/12/2009

**Last updated:** 17/12/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bondronat_en.pdf)

Bondronat : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (98.72 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/bondronat-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

Bondronat-H-C-101-II-49 : EPAR - Scientific Discussion - Variation

Adopted

Reference Number: EMA/CHMP/795694/2009

English (EN) (80.47 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 08/03/2010

[View](/en/documents/scientific-discussion-variation/bondronat-h-c-101-ii-49-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Bondronat : EPAR - Scientific Discussion

English (EN) (324.76 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/bondronat-epar-scientific-discussion_en.pdf)

Bondronat : EPAR - Procedural steps taken before authorisation

English (EN) (81.35 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/bondronat-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Bondronat

[European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection](/en/news/european-medicines-agency-finalises-review-medicines-concerned-roche-pharmacovigilance-inspection) 19/11/2013

[European Medicines Agency starts infringement procedure to investigate Roche's alleged non-compliance with pharmacovigilance obligations](/en/news/european-medicines-agency-starts-infringement-procedure-investigate-roches-alleged-non-compliance-pharmacovigilance-obligations) 23/10/2012

[European Medicines Agency concludes class review of bisphosphonates and atypical fractures](/en/news/european-medicines-agency-concludes-class-review-bisphosphonates-atypical-fractures) 15/04/2011

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 16/09/2024

## Share this page

[Back to top](#main-content)